Author

Miku Ito

Institution: Johnson & Johnson K.K. (Japan)

Observed institutions: Johnson & Johnson (United States), Janssen Pharmaceutical K.K. (Japan), Johnson & Johnson K.K. (Japan)

ORCID: 0000-0001-7773-1360

Observed ORCID: 0000-0001-7773-1360

OpenAlex ID: A5049705959

Clinical Outcomes of Patients with High-risk Metastatic Hormone-naïve Prostate Cancer: A 3-year Interim Analysis of the Observational J-ROCK Study

2024 · Hideaki Miyake, Rikiya Matsumoto, et al. · European Urology Oncology · 29

Safety and efficacy of apalutamide in Japanese patients with metastatic castration‐sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo‐controlled, phase III TITAN study

2022 · Hirotsugu Uemura, Gaku Arai, et al. · International Journal of Urology · 26

Treatment strategies and outcomes in a long‐term registry study of patients with high‐risk metastatic hormone‐naïve prostate cancer in Japan: An interim analysis of the J‐ROCK study

2022 · Hirotsugu Uemura, Rikiya Matsumoto, et al. · International Journal of Urology · 14

Japanese subgroup analysis of AQUILA trial: daratumumab vs active monitoring in high-risk smoldering multiple myeloma

2026 · Kenshi Suzuki, Hiroshi Kosugi, et al. · Japanese Journal of Clinical Oncology

Daratumumab plus VRd in Japanese transplant-ineligible/deferred NDMM patients: Japanese subgroup of the CEPHEUS trial

2026 · Kenshi Suzuki, Morio Matsumoto, et al. · International Journal of Hematology

Correlation between duration of first-line treatment with daratumumab, lenalidomide, and dexamethasone and overall survival in patients with transplant-ineligible multiple myeloma in Japan

2025 · Kazuhito Suzuki, Miku Ito, et al. · Current Medical Research and Opinion

Works count: 6

Citation count: 69

H-index: 3

I10-index: 3